25% Drop Sets Off Sarepta Therapeutics Inc (SRPT) Options Trading

Eteplirsen's prospects at the FDA look bleak -- and Sarepta Therapeutics Inc (SRPT) shares are paying the price

Jun 2, 2016 at 2:05 PM
facebook X logo linkedin

Sarepta Therapeutics Inc (NASDAQ:SRPT) has shed roughly one-quarter of its value today at $16.01, and landed on the short-sale restricted list. Taking a toll on the stock are rumblings the U.S. Food and Drug Administration (FDA) could pressure the drugmaker to provide its Duchenne muscular dystrophy (DMD) treatment, eteplirsen, to patients at cost -- rather than granting it accelerated approval. Amid the news, SRPT options are flying off the shelves.

At last check, over 68,000 options are on the tape -- tripling the expected intraday amount. The most active strike is the June 30 call, where it's possible traders may be purchasing new positions to bet on a big bounce by front-month expiration, at the close on Friday, June 17. Clearer-cut buy-to-open (BTO) activity is detected at SRPT's weekly 6/10 25-strike call, as option bulls expect a rally past the quarter-century mark by next Friday's close, when the weekly series expires.

Longer term, though, put buying has been accelerated. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), SRPT's 50-day put/call volume ratio of 0.57 registers just 4 percentage points from a 12-month peak. Likewise, short-term open interest levels are tilted in a relatively put-skewed direction. This, based on the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.56, which ranks in the high 86th annual percentile.

Outside of the options pits, doubters abound. Short interest surged over 23% during the last two reporting periods, and now accounts for over three-fifths of the stock's float. As such, some of today's BTO activity at the out-of-the-money calls could be a result of shorts hedging their bearish bets against any upside risk. Elsewhere, 10 of 13 analysts rate SRPT a "hold" or worse.

Today's FDA rumors have certainly been a boon to bears. In fact, in a research note, Jefferies described eteplirsen's chances of receiving regulatory approval as "slim." If that becomes official, it may serve as another setback for SRPT stock.

Suffice it to say, Sarepta Therapeutics Inc (NASDAQ:SRPT) has gotten bloodied up on the charts -- and not just today. Since the start of 2016, the shares have surrendered over 58% of their value, and are poised to close below their 80-day moving average for the first time since late April.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI